Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02029443
Title ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

prolymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

diffuse large B-cell lymphoma

Therapies

Acalabrutinib

Age Groups: adult
Covered Countries USA | ITA

Facility Status City State Zip Country Details
Research Site Boston Massachusetts 2215 United States Details
Research Site New Hyde Park New York 11042 United States Details
Research Site New York New York 10021 United States Details
Research Site Columbus Ohio 43210 United States Details
Research Site Fort Worth Texas 76104 United States Details
Research Site Salt Lake City Utah 84112 United States Details
Research Site Seattle Washington 98122 United States Details
Research Site Tacoma Washington 98405 United States Details
Research Site Milano 20132 Italy Details
Research Site Leeds LS9 7TF United Kingdom Details
Research Site London SE5 9RS United Kingdom Details
Research Site Oxford OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field